Company profile
Agenus Inc.
Pipeline14 assets
- BotensilimabAGEN1181 / Anti-CTLA-4 / Fc-enhanced anti-CTLA-4 antibody / OncologyNon-MSI-H 4L+ metastatic colorectal cancerPhase 3Sites activeNon-MSI-H metastatic colorectal cancer NLMPhase 2Enrollment completePD-1 R/R melanomaPhase 2
- BalstilimabAGEN2034 / Anti-PD-1 / PD-1 inhibitor antibody / OncologyMSS metastatic colorectal cancer in combination with botensilimabPhase 3Sites activePD-1 R/R melanoma in combination with botensilimabPhase 2
- AGEN2373AGEN2373 / CD137 / CD137 agonist antibody / OncologySolid tumorsPhase 1PD-1 R/R melanoma with botensilimabPhase 2
- AGEN1571AGEN1571 / Anti-ILT-2 / Antibody / OncologySolid tumorsPhase 1
- AGEN1777AGEN1777 / Anti-TIGIT x CD96 / Bispecific antibody / OncologySolid tumors with balstilimabPhase 1
- AGEN1423AGEN1423 / Anti-CD73 x TGFB / Bispecific antibody / OncologySolid tumorsPhase 1
- INCAGN1876INCAGN1876 / Anti-GITR / Antibody / OncologySolid tumorsPhase 1
- AGEN1949AGEN1949 / OX40 / OX40 agonist antibody / OncologySolid tumorsPhase 1
- MK-4830MK-4830 / ILT4 / Anti-ILT4 antagonist antibody / OncologyNeoadjuvant ovarian cancerPhase 2Ongoing
- INCAGN2390INCAGN2390 / TIM-3 / Anti-TIM-3 antagonist antibody / OncologyMelanoma and SCCHN in combinationIn development
- INCAGN2385INCAGN2385 / LAG-3 / Anti-LAG-3 antagonist antibody / OncologyMelanoma and SCCHN in combinationIn development
- CR6086 + BalstilimabCR6086; AGEN2034 / EP4 + PD-1 / EP4 antagonist plus PD-1 antagonist / OncologypMMR-MSS colorectal cancerPhase 1/2Ongoing
- NLM001 + ZalifrelimabNLM-001 / Hedgehog + CTLA-4 / Hedgehog inhibitor plus CTLA-4 antagonist / OncologyAdvanced pancreatic cancerPhase 1/2Ongoing
- OBT076 + BalstilimabOBT076; AGEN2034 / CD205 + PD-1 / Antibody-drug conjugate plus PD-1 antibody / OncologySolid tumorsOngoing
Latest news15 items
All newsAgenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
Presentation / Abstract • Phase 2